Talaris lays off 95% of workforce, C-suite as kidney transplant company fails to find a savior

Talaris Therapeutics was already put on life support back in February, when the biotech axed two kidney transplant trials along with a third of its staff. Now, the company is letting go of 95% of remaining employees.